Full-Time

Clinical Trial Manager

Nephrology

Updated on 9/4/2026

Deadline 1/15/27
Medpace

Medpace

5,001-10,000 employees

Global CRO delivering full-service clinical trials

No salary listed

Lyon, France

Hybrid

Office-based role with occasional work from home for eligible positions after training.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Medpace

See people who can refer or advise you

Requirements
  • A bachelor's degree in a health or life science-related field is required.
  • A minimum of 5 years of Clinical Trial Management experience is required.
  • Experience managing overall project timelines is required.
Responsibilities
  • Manage and provide accountability for day-to-day project operations according to the contract, ICH/GCP, and applicable laws, rules, and regulations.
  • Serve as the primary Sponsor contact for operational project-specific issues and study deliverables.
  • Maintain in-depth knowledge of the protocol, therapeutic area, and indication.
  • Provide cross-functional oversight of internal project team members and deliverables, including ensuring that necessary project-specific training is provided.
  • Review and provide input for the study protocol, edit check specifications, data analysis plan, and final study report when applicable.
  • Develop operational project plans.
  • Manage risk assessment and execution.
  • Manage study vendors.
  • Manage site quality, including direct supervision of project Clinical Research Associates and monitoring deliverables.
Desired Qualifications
  • Advanced degree in a health or life science-related field.
  • Experience in clinical trial Phases 2–3.
  • CRO experience.
  • Bid defense experience.

Medpace is a global Contract Research Organization that provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device leaders. It runs Phase I–IV trials from study design through regulatory submissions, monitoring, data management, statistics, medical writing, and final reporting. A unique feature is ownership of integrated laboratories—global central labs, a bioanalytical lab, and imaging/ECG core labs—that streamline workflows and ensure data consistency. Its goal is to help sponsors bring therapies to market efficiently by coordinating all trial activities under a physician-led, scientifically driven team.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cincinnati, Ohio

Founded

1992

Get referred to Medpace

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $707.3 million, up 17.2%, with 1.13x book-to-bill.
  • Medpace raised 2026 revenue guidance to $2.805 billion-$2.885 billion on July 23, 2026.
  • Zelluna chose Medpace on February 11, 2026 for its first-in-human TCR-NK trial.

What critics are saying

  • Durbin v. Medpace alleges February 2026 book-to-bill inflation; discovery runs through 2027.
  • Late-stage biotech funding freezes can stall clients, crushing backlog conversion within quarters.
  • If cancellations stay elevated, Medpace loses trust and full-service differentiation becomes commoditized.

What makes Medpace unique

  • August Troendle still runs Medpace with a physician-led, science-first operating model.
  • Medpace bundles CRO, central lab, bioanalytical, imaging, and ECG services in-house.
  • It specializes in small and mid-sized biotech sponsors needing full-service trial execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Unlimited Paid Time Off

Competitive Compensation and Benefits Package

Employee Health and Wellness Initiatives

Hybrid Work Options

Structured Career Paths with Opportunities for Professional Growth

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
American Market News
Sep 3rd, 2026
Hsbc Holdings PLC Makes New Investment in Medpace Holdings, Inc. $MEDP

Hsbc Holdings PLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 977 shares of the company’s stock, valued at approximately $518,000. Several other hedge funds and other institutional […]

Yahoo Finance
Aug 17th, 2026
Medpace leads drug development services sector with $707M Q2 revenue, up 17.2% year-on-year

Medpace reported revenues of $707.3 million in Q2, up 17.2% year on year, exceeding analyst expectations by 2.6%. The contract research organisation, which provides outsourced clinical trial management services to pharmaceutical and biotech companies, achieved the fastest revenue growth among eight drug development inputs and services stocks tracked. The company's full-year revenue guidance surpassed analyst expectations. The sector overall performed strongly, with revenues beating consensus estimates by 4.1% and share prices rising 10.5% on average since earnings. Medpace's stock rose 10.2% following the results and currently trades at $582.23. The drug development inputs and services industry benefits from stable demand as pharmaceutical companies outsource non-core functions through medium to long-term contracts.

Yahoo Finance
Jul 22nd, 2026
Medpace beats Q2 revenue expectations by 2.6%, stock surges 18.6%

Medpace reported second-quarter revenue of $707.3 million, exceeding analyst estimates of $689.7 million and marking 17.2% year-on-year growth. The clinical research company's GAAP profit of $4.25 per share beat consensus estimates by 6.6%. The company raised its full-year revenue guidance to $2.85 billion at the midpoint, up from $2.81 billion previously. Full-year EPS guidance of $17.60 at the midpoint came in 3.9% above analyst expectations. Medpace's stock jumped 18.6% following the results. The company's adjusted EBITDA of $153.4 million also exceeded estimates, delivering a 21.7% margin. Despite the strong performance, analysts expect revenue to remain flat over the next 12 months, suggesting potential demand challenges ahead.

Yahoo Finance
Jul 21st, 2026
Medpace Q2 earnings preview: revenue expected to grow 14.3% year on year

Clinical research company Medpace Holdings will report its second-quarter earnings on Wednesday after market hours. The market expects Medpace's revenue to grow 14.3% year on year this quarter, in line with the 14.2% increase it recorded in the same quarter last year. In the previous quarter, Medpace reported revenues of $706.6 million, up 26.5% year on year, beating analysts' expectations. The company also exceeded EPS estimates, though its full-year EPS guidance aligned with analysts' forecasts. Analysts covering the company have generally reconfirmed their estimates over the last 30 days. Medpace shares have risen 15.8% over the past month, outperforming the life sciences tools and services segment average of 9.9%.

Yahoo Finance
Jun 18th, 2026
Medpace Holdings gains 51% as Turtle Creek adds $13B CRO to portfolio

Turtle Creek Asset Management added Medpace Holdings, Inc. (NASDAQ:MEDP) to its portfolio in Q1 2026, citing the clinical research organisation's differentiated strategy. The company focuses on small and mid-sized biopharma companies with full-service offerings, whilst competitors mainly serve Big Pharma with lower-margin work. Medpace's clinician-led model employs full-time MDs and PhDs to develop expertise in complex therapeutic areas. The founder-run company has demonstrated strong growth and cash flow generation. Its capital allocation approach is notably opportunistic, accumulating cash when shares are expensive and repurchasing aggressively when undervalued—buying back nearly 10% of outstanding shares last year. In Q1 2026, Medpace reported revenue of $706.6 million, up 26.5% year-over-year. Shares closed at $475.07, with a market capitalisation of $13.05 billion.